PT - JOURNAL ARTICLE AU - Sakiko Tabata AU - Kazuo Imai AU - Shuichi Kawano AU - Mayu Ikeda AU - Tatsuya Kodama AU - Kazuyasu Miyoshi AU - Hirofumi Obinata AU - Satoshi Mimura AU - Tsutomu Kodera AU - Manabu Kitagaki AU - Michiya Sato AU - Satoshi Suzuki AU - Toshimitsu Ito AU - Yasuhide Uwabe AU - Kaku Tamura TI - Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship “Diamond Princess” in Japan AID - 10.1101/2020.03.18.20038125 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.18.20038125 4099 - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038125.short 4100 - http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038125.full AB - Background The ongoing outbreak of 2019 novel coronavirus disease (COVID-19) is a global threat. Clarifying its clinical features such as risk factors for disease progression is a pressing issue. We analyzed the difference between non-severe and severe cases with COVID-19 as a result of the mass infection on a cruise ship “Diamond Princess” in Japan.Methods In this retrospective, single-center study, total 104 cases of laboratory-confirmed COVID-19 were enrolled from the mass infection on the cruise ship from 11th to 25th Feb, 2020, at Self-Defense Forces Central Hospital in Japan. Clinical records, laboratory data, and radiological findings were collected and analyzed. Clinical outcomes were followed up until 26th Feb, 2020.Findings Of the 104 patients, 47 were male. The median age was 68 years. During the observation period, eight patients deteriorated into the severe cases. Finally, 76 and 28 patients were classified as non-severe (asymptomatic, mild), and severe cases, respectively. Chest CT abnormalities were found in 43 in non-severe cases and 23 in severe cases. The prevalence of consolidation on chest CT scan and lymphopenia on the admission day was significantly higher in severe cases and in the eight cases which worsened into severe disease during the observation period.Interpretation The high proportion of non-severe cases corrects the assessment of the trend of the outbreak. Consolidation on chest CT scan and lymphopenia were possible risk factors for deterioration of COVID-19 and contribute to the clinical management.Funding Not applicable.Research in context Evidence before this study We looked into PubMed database for articles published in English up to 1st, Mar, 2020, using the keywords “novel coronavirus”, “2019 novel coronavirus”, “2019-nCoV”, “Severe acute respiratory syndrome coronavirus 2”, “SARS-CoV2”, “COVID-19”, “mass infection”, “herd infection”, “cruise ship”, “Diamond Princess”, “asymptomatic” and “subclinical”. There were no published clinical studies of featuring COVID-19 as a result of mass infection of cruise ship. We found a published researches entitled “Characteristics of COVID-19 infection in Beijing.”, and “Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study” comparing patients with COVID-19 between asymptomatic, mild, and severe cases. However, above researches did not describe the marker of deterioration, or the risk factors for disease progression.Added value of this study We presented a high proportion of asymptomatic and mild cases in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). On the admission day, the prevalence of consolidation detected by CT scan and lymphopenia were significant higher in severe cases and in cases which deteriorated into sever cases during the observation period. Consolidation on CT scan and lymphopenia reflect the disease progression. This report contributes to the improvement of the epidemiological and clinical management of COVID-19.Implications of all the available evidence There is a high prevalence of non-severe cases in patients infected with COVID-19 as a result of the mass infection on a cruise ship. The prevalence of asymptomatic and mild cases of COVID-19 contributes to the further assessment on the trend of outbreak. Consolidation detected by CT scan and lymphopenia are useful for the markers of disease progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicable.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.